210 results on '"Saenger, Yvonne"'
Search Results
2. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation
3. Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States
4. Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients
5. 750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
6. An update on methods for detection of prognostic and predictive biomarkers in melanoma
7. Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients
8. Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma
9. Supplemental Figure S3 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
10. Supplemental Methods from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
11. Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
12. Supplemental Figure Legends from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
13. Supplemental Figure S2 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
14. Data from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
15. Supplemental Figure S5 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
16. Supplemental Figure S1 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
17. Supplemental Methods from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
18. Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
19. Supplemental Figure S5 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
20. SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
21. Supplemental Figure S1 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
22. Supplemental Figure S4 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
23. Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
24. Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
25. Supplemental Figure Legends from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
26. Supplementary Table S2 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
27. Supplemental Figure S4 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
28. Data from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
29. Supplementary Table S3 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
30. Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
31. Supplemental Figure S2 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
32. SupplementaryTable S4 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
33. Supplementary Table S1 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
34. Supplemental Figure S3 from Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
35. Supplemental Table S1-4 and Supplemental Figure S1-S7 from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
36. Data from Quantitative Analysis of Immune Infiltrates in Primary Melanoma
37. Supplemental Table ST2 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
38. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
39. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
40. Supplemental Figure S3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
41. Data from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
42. Supplemental Table ST3 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
43. Supplemental Table ST1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
44. Figure S3 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
45. Supplemental Table ST1 from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
46. Supplemental Figure Legends from Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma
47. Table S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
48. Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
49. Figure S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
50. Supplementary Table S1: Additional metastatic pancreatic adenocarcinoma trials from Current and Emerging Therapies in Metastatic Pancreatic Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.